- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Peripheral T-Cell Lymphoma Genome Cracked Open
Researchers at the Mayo Clinic in Rochester have completed the first known genome-wide analysis of peripheral T-cell lymphomas (PTCL).
According to their research, published in Blood, the journal of the American Society of Hematology, and titled, "Genome-wide Analysis Reveals Recurrent Structural Abnormalities of TP63 and other p53-related Genes in Peripheral T-cell Lymphomas" a number of genomic abnormalities have been discovered that should help researchers develop more targeted therapies against PTCLs, such as:
- PTCLs feature at least 13 chromosomal rearrangements
- Five of them involve p53 genes
- Two newly uncovered ones, TP53 and TP63, indicate a poorer prognosis
T-cell lymphomas are underclassified
This is good news for in the world of T-cell lymphomas. Long the poorly understood and widely ignored step-child to lymphomas of B-cell origin, T-cell lymphomas in general have a poorer prognosis than B-cell lymphomas, and remain extremely under-classified.
In fact, while there are a handful of PTCL subtype classifications, more often than not the diagnosis for many patients is PTCL-NOS, or peripheral T-cell lymphoma not otherwise specified, a classification that Mayo researcher Andrew Feldman refers to as a "wastebasket diagnosis" because it includes so many variations that remain poorly understood, if understood at all.
One of the hopes from having carried out the first genome-wide look at PTCLs is that not only will it lead to better therapies, but that accuracy in diagnosis will improve. While accurate diagnoses of most cancers, including B-cell lymphomas, can be made by most pathologists, T-cell lymphomas are so difficult to diagnose that second opinions ought to be mandatory, and they should always be made by a certified blood pathologist.
"Every time I diagnose a peripheral T-cell lymphoma, I know that two out of three patients will succumb to that lymphoma," said Feldman. "That's a very unsatisfying feeling, and I hope that our research can help change those statistics."
Source: Mayo Clinic